Industry Profile: Optos
September 20, 2011
Optos’ vision is to be recognized as a leading provider of devices and solutions to eye care professionals for improved patient care. At the core of the Optos product family are devices that produce ultra-widefield, high resolution digital images of approximately 82 percent of the retina, something no other device is capable of doing in a single, non-contact image capture. The optomap® image provides optometrists with enhanced clinical data that often exhibits first in the periphery of the retina. This information facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers.
At the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale May 1-4, 2011, 20 positive clinical studies involving data from optomap images were presented. The abstracts reinforced the importance of the periphery in the diagnosis and management of retinal disease as well as provided support for the ability to obtain high-quality images of the central pole. optomap was demonstrated to provide a clinically useful image through dense cataracts and serve as a valuable tool for the management of uveitis, diabetic retinopathy and glaucoma. Further, an early study investigating the use of Optos’ retinal imaging device for detecting and monitoring Alzheimer’s Disease showed it could provide visualization of a potential biomarker for the disease.
Understanding the varied needs in eye care, Optos offers a full range of complementary retinal imaging devices. The newest product is the 200Dx, which provides the same ultra-widefield view with enhanced image quality, such as a brighter superior field, a better distribution of light and greater detail in the central pole. Added software features include historical image overlay, a localized magnifier tool, and the ability to capture as a movie file a 3-D animation. In addition to the core retinal imaging technology the Optos’ product range has expanded to include the AccuPen, PachPen and B-Scan handheld devices for additional patient assessments. The acquisition of Opto Global in 2010, brought new products for visual acuity and perimetry. Another key introduction is OptosAdvance a fast, efficient image archiving, referral management and image retrieval software with full EMR integration capabilities. The continued product enhancements and introductions in Optos’ product line positions the company to attain its goal of building The retina company.
Optos plc is headquartered in Dunfermline, Scotland, and was admitted to the Main Market of the London Stock Exchange on Feb. 15, 2006, trading under the symbol OPTS. Optos’ North American headquarters is based in Marlborough, MA. For more information about the company or products please visit www.optos.com.
